• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Seres Therapeutics Inc (NQ: MCRB )

    1.230 UNCHANGED
    Streaming Delayed Price Updated: 3:45 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,507,542
    Open 1.250
    Bid (Size) 1.220 (42)
    Ask (Size) 1.230 (81)
    Prev. Close 1.230
    Today's Range 1.205 - 1.275
    52wk Range 0.5400 - 5.290
    Shares Outstanding 127,901,391
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    -12.14%
    -12.14%
    1 Month
    +58.53%
    +58.53%
    3 Month
    +96.93%
    +96.93%
    6 Month
    -1.60%
    -1.60%
    1 Year
    -71.98%
    -71.98%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Seres Therapeutics's Earnings: A Preview
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
    Via Benzinga
    Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
    Via InvestorPlace
    MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
    From Seres Therapeutics, Inc.
    Via Business Wire
    Earnings Scheduled For March 5, 2024
    Via Benzinga
    Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.